Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: RETRACTED ARTICLE: Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer

Fig. 7

TINCR is transcriptionally activated by H3K27 acetylation at the TINCR promoter region. a The genome bioinformatics analysis showed that the promoter of TINCR had a high enrichment of H3K27ac. b The enrichment of H3K27ac at TINCR promoter was assessed via ChIP assay in both trastuzumab-resistant cells and parental cells. *P < 0.05 compared to parental cells. c The H3K27ac enrichment was measured by ChIP experiment in 5 responding patients and 5 non-responding patients, *P < 0.05. d TINCR expression was measured by qPCR in breast cancer cells treated with C646 or DMSO for 48 h. *P < 0.05 compared to DMSO treatment group. e ChIP assay by using CBP antibody tested the enrichment at TINCR promoter, *P < 0.05. f CBP protein level was assessed by Western blot assay in cells silenced with CBP. g The enrichment of H3K27ac at the promoter region of TINCR was measured by ChIP assay in cells silenced with CBP. *P < 0.05 compared to si-NC. h TINCR expression was assessed by qPCR in cells silenced with CBP. *P < 0.05 compared to si-NC

Back to article page

Molecular Cancer

ISSN: 1476-4598